A Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex
- 16 May 2013
- journal article
- research article
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 28 (7) , 933-936
Abstract
Facial angiofibromas are dermatological manifestations of tuberous sclerosis complex, a neurocutaneous disorder characterized by excess cell growth and proliferation. Oral rapamycin has been used to treat visceral tuberous sclerosis–related tumors; however, the side effect profile of this medicine precludes its routine use in patients lacking significant internal involvement. The authors formulated a novel rapamycin cream that is easy to compound and apply, does not cause local or systemic side effects, and results in a dramatic improvement of facial angiofibromas.Keywords
This publication has 16 references indexed in Scilit:
- Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis ComplexDrugs in R&D, 2012
- Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patientsAustralasian Journal of Dermatology, 2011
- Tratamento dos angiofibromas múltiplos da face com radiofrequênciaAnais Brasileiros de Dermatologia, 2011
- A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severityBritish Journal of Dermatology, 2011
- Treatment of facial angiofibromas with topical application of oral rapamycin solution (1 mg mL −1 ) in two patients with tuberous sclerosisBritish Journal of Dermatology, 2011
- Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patientRenal Failure, 2010
- New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosisLasers in Surgery and Medicine, 2010
- Facial angiofibromas of tuberous sclerosis: successful treatment with podophyllinJournal of the European Academy of Dermatology and Venereology, 2009
- The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosisBritish Journal of Dermatology, 2008
- Treatment of Facial Angiofibroma of Tuberous Sclerosis Using Cultured Epithelial AutograftsAnnals of Plastic Surgery, 2006